Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Gyre Therapeutics, Inc. (L9S.F)

Compare
6.75
+0.15
+(2.27%)
At close: April 15 at 8:05:43 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for L9S.F

Recent News: L9S.F

View More
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewswire 15 days ago
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings

We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
Simply Wall St. 19 days ago
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
GlobeNewswire 19 days ago
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. 27 days ago
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire 29 days ago
Exploring High Growth Tech Stocks In The US March 2025

Exploring High Growth Tech Stocks In The US March 2025
Simply Wall St. last month
Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors

Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
GlobeNewswire 3 months ago
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)

Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023)
Simply Wall St. 4 months ago
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
GlobeNewswire 4 months ago
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis

Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
GlobeNewswire 5 months ago
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt

Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt
Simply Wall St. 6 months ago
View More

Related Tickers

D01.BE BELITE BIO INC. R
51.50
+1.98%
 
87S.MU Roivant Sciences Ltd
8.90
+1.78%
 
BH3.SG PTC Therapeutics Inc
38.80
+4.86%
 
9LB.DU Legend Biotech Corp
30.20
+7.09%
 
BH3.BE PTC Therapeutics Inc
41.20
+3.52%
 
87S.DU Roivant Sciences Ltd
8.78
-1.35%
 
DUL.SG Alnylam Pharmaceuticals Inc
209.60
-0.33%
 
ATQP.SG Vericel Corp
37.00
+2.21%
 
6XC.F Soleno Therapeutics, Inc.
59.15
+4.51%
 
41X.SG Ardelyx Inc
4.0540
-0.86%